CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company’s first quarter 2023 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: ir.wavelifesciences.com/events-and-presentations.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alicia Suter
617-949-4817
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$15.06 |
| Daily Change: | 0.17 1.14 |
| Daily Volume: | 18,668 |
| Market Cap: | US$1.880B |
November 26, 2024 November 12, 2024 October 30, 2024 October 16, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
